Get the Stockscreener App
6.205
6.47%
-0.445
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Altimmune Inc stock is traded at $6.205, with a volume of 1.33M.
It is down -6.47% in the last 24 hours and down -3.42% over the past month.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
See More
Previous Close:
$6.65
Open:
$6.71
24h Volume:
1.33M
Relative Volume:
0.53
Market Cap:
$460.96M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-3.7835
EPS:
-1.64
Net Cash Flow:
$-71.49M
1W Performance:
+1.80%
1M Performance:
-3.42%
6M Performance:
-2.51%
1Y Performance:
-48.55%
1-Day Range:
$6.185
$6.71
1-Week Range:
$5.80
$6.78
52-Week Range:
$5.275
$12.35
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune Inc
Sector
Industry
Phone
(240) 654-1450
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
6.205 | 460.96M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.20 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.92 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
635.87 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.13 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.59 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Nov-12-24 | Initiated | UBS | Buy |
| Apr-29-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-24-24 | Initiated | Goldman | Neutral |
| Mar-22-23 | Downgrade | Goldman | Buy → Neutral |
| Dec-01-22 | Initiated | Goldman | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-02-21 | Initiated | H.C. Wainwright | Buy |
| Feb-11-21 | Initiated | Guggenheim | Buy |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Nov-12-20 | Reiterated | B. Riley Securities | Buy |
| Sep-25-20 | Initiated | B. Riley FBR | Buy |
| Aug-14-20 | Initiated | Evercore ISI | Outperform |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-28-20 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-20 | Resumed | ROTH Capital | Buy |
| Jul-19-19 | Initiated | ROTH Capital | Buy |
| Oct-09-17 | Initiated | Piper Jaffray | Overweight |
View All
Altimmune Inc Stock (ALT) Latest News
Altimmune to Participate in the Leerink Global Healthcare Conference - Yahoo Finance
ALTIMMUNE, INC. (NASDAQ: ALT) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Altimmune, Inc. - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of Altimmune, Inc.(ALT) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
William Blair Begins Coverage on Altimmune (NASDAQ:ALT) - MarketBeat
Altimmune Inc (ALT) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising R&D Costs - GuruFocus.com
Brokerages Set Altimmune, Inc. (NASDAQ:ALT) Target Price at $20.83 - MarketBeat
Altimmune, Inc. (NASDAQ:ALT) Q4 2024 Earnings Call Transcript - MSN
William Blair Initiates Coverage of Altimmune (ALT) with Market Perform Recommendation - Nasdaq
Altimmune (NASDAQ:ALT) Releases Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due In Q2 - Seeking Alpha
William Blair Initiates Coverage of Altimmune (LSE:0A4C) with Market Perform Recommendation - Nasdaq
Altimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 Print - MSN
Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your RightsALT - ACCESS Newswire
Altimmune Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance
Altimmune, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationALT - ACCESS Newswire
Altimmune Reports Progress in Clinical Trials and Financials - TipRanks
Shareholders that lost money on Altimmune, Inc. (ALT) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Altimmune, Inc. to Host Earnings Call - ACCESS Newswire
Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire
Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024ALT - ACCESS Newswire
Altimmune Files For Mixed Shelf Offering Of Up To $400 Million- SEC Filing -February 27, 2025 at 05:34 pm EST - Marketscreener.com
Altimmune reports Q4 EPS (33c), consensus (34c) - TipRanks
Earnings call transcript: Altimmune Q4 2024 sees stock surge 7.41% - Investing.com
Altimmune Reports 2024 Financial Results and R&D Progress - TipRanks
ALTIMMUNE Earnings Results: $ALT Reports Quarterly Earnings - Nasdaq
Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - The Manila Times
UPCOMING ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors - citybiz
Altimmune Expands Board Amid Late-Stage Drug Development - TipRanks
Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors - The Manila Times
Can These Two Industry Veterans Transform Altimmune's Commercial Future? Key Appointments Signal Major Shift - StockTitan
Altimmune (NASDAQ:ALT) Trading 8.7% HigherTime to Buy? - MarketBeat
Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight - GlobeNewswire Inc.
Levi & Korsinsky Reminds Altimmune, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024ALT - ACCESS Newswire
Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 - The Manila Times
ALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
When Will Altimmune Report Q4 Earnings? Key Date and Details for Biotech Investors - StockTitan
Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH - Seeking Alpha
Investigation announced for Long-Term Investors in shares - openPR
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
Altimmune (NASDAQ:ALT) Earns "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright maintains Buy on Altimmune stock, $12 target - MSN
Analysts Set Altimmune, Inc. (NASDAQ:ALT) Target Price at $20.83 - MarketBeat
BlackRock, Inc.'s Strategic Acquisition of Altimmune Inc Shares - GuruFocus.com
With 56% institutional ownership, Altimmune, Inc. (NASDAQ:ALT) is a favorite amongst the big guns - Yahoo Finance
Analysts Set Altimmune, Inc. (NASDAQ:ALT) PT at $20.83 - MarketBeat
IMMINENT ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
Altimmune Inc Stock (ALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Altimmune Inc Stock (ALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Garg Vipin K | President and CEO |
Feb 01 '25 |
Option Exercise |
0.00 |
16,545 |
0 |
351,645 |
| Garg Vipin K | President and CEO |
Jan 30 '25 |
Option Exercise |
0.00 |
26,775 |
0 |
342,696 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
84,564 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
78,898 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
74,000 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
75,536 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
69,562 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
62,921 |
| Roberts M Scot | Chief Scientific Officer |
Jan 25 '25 |
Option Exercise |
0.00 |
14,600 |
0 |
57,910 |
| Jordt Raymond M | Chief Business Officer |
Jan 25 '25 |
Option Exercise |
0.00 |
14,600 |
0 |
36,150 |
3.91%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):